Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kosan down on Phase Ib MM data

KOSN fell $2.47 (43%) to $3.31 on Monday after reporting that 340 mg/m2 of its

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE